Pascal Biosciences Awarded NIH Grant For Leukemia Program

Author's Avatar
Jun 08, 2021

VANCOUVER, BC / ACCESSWIRE / June 8, 2021 / Pascal Biosciences Inc. ("Pascal" or the "Company") (TSXV:PAS, Financial)(OTC PINK:PSCBF), has been awarded a grant of US$343,750 from the National Cancer Institute of the US National Institutes of Health (NIH). This two-year award will fund development of Pascal's antibody drug for Acute Lymphoblastic Leukemia (ALL), which is the most common childhood leukemia.